[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100603063":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":30,"centralContacts":35,"locations":44,"responsibleParty":60,"collaborators":29,"id":63,"slug":29,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":29,"eligibilityCriteria":68,"healthyVolunteers":64,"sex":69,"minAge":29,"maxAge":29,"enrollmentInfo":70,"targetDuration":29,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":79,"overallStatus":81,"whyStopped":29,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"West China Hospital","OTHER",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Direct discontinuation group","PLACEBO_COMPARATOR","Sirolimus was gradually tapered and discontinued over a 2-month period.",[13],"Drug: Sirolimus",{"label":15,"type":16,"description":17,"interventionNames":18},"Low-dose treatment group","EXPERIMENTAL","Low-dose sirolimus treatment was administered for 6 months (with blood levels maintained at 2-5 ng\u002FmL), followed by gradual tapering and discontinuation over 2 months.",[13],{"label":20,"type":16,"description":21,"interventionNames":22},"Intermittent treatment group","Sirolimus was administered using a 3-days-on\u002F4-days-off weekly schedule for 6 months, followed by gradual tapering and discontinuation over 2 months.",[13],[24],{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":29},"DRUG","Sirolimus","Comparison of different sirolimus discontinuation strategies.",[9,20,15],null,[31],{"name":32,"affiliation":33,"role":34},"Yi Ji, PhD","Sichuan University West China Hospital","PRINCIPAL_INVESTIGATOR",[36,40],{"name":32,"role":37,"phone":38,"phoneExt":29,"email":39},"CONTACT","+862885423453","jijiyuanyuan@163.com",{"name":41,"role":37,"phone":42,"phoneExt":29,"email":43},"Jiangyuan Zhou, Doctor","+8613668491160","13668491160@163.com",[45],{"facility":46,"status":29,"city":47,"state":48,"zip":49,"country":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"West China Hospital of Sichuan University","Chengdu","Sichuan","610041","China",{"type":52,"coordinates":53},"Point",[54,55],104.06667,30.66667,{"lat":55,"lon":54},[58,59],{"name":32,"role":37,"phone":38,"phoneExt":29,"email":39},{"name":41,"role":37,"phone":29,"phoneExt":29,"email":43},{"type":34,"investigatorFullName":61,"investigatorTitle":62,"investigatorAffiliation":5,"oldNameTitle":29,"oldOrganization":29},"Yi Ji","MD, PhD","100603063",false,"NCT07131644","Sirolimus Discontinuation Strategies in Kaposiform Hemangioendothelioma","A Randomized Controlled Trial Comparing Three Sirolimus Discontinuation Strategies in Patients With Kaposiform Hemangioendothelioma","Inclusion Criteria:\n\n* KHE patients who have received sirolimus treatment and met the criteria for drug discontinuation.\n* With evaluable clinical or imaging parameters to monitor disease activity or recurrence.\n* Patients or their guardians are able to understand the study and provide written informed consent.\n* Hematologic and hepatic\u002Frenal function meet the safety criteria for drug administration.\n\nExclusion Criteria:\n\n* Patients who are unable to comply with the follow-up or treatment schedule, potentially affecting the integrity of study data.","ALL",{"count":71,"type":72},120,"ESTIMATED","INTERVENTIONAL",[75],"PHASE2","Sirolimus has demonstrated efficacy in the treatment of kaposiform hemangioendothelioma (KHE); however, a high rate of rebound growth following discontinuation has been reported, highlighting the clinical importance of establishing an appropriate withdrawal regimen.",[78],"Kaposiform Hemangioendothelioma",[78,26,80],"Discontinuation Strategies","NOT_YET_RECRUITING","2025-09-01",{"date":84,"type":85},"2025-09-08","ACTUAL",{"date":87,"type":72},"2025-09-13",{"date":89,"type":72},"2028-02-01",{"name":5,"class":6},1]